Display options
Cite
Seino H, Onishi Y, Naito Y, et al. Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr. 2016;8:36doi: 10.1186/s13098-016-0151-7.
Seino, H., Onishi, Y., Naito, Y., & Komatsu, M. (2016). Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetology & metabolic syndrome, 836. https://doi.org/10.1186/s13098-016-0151-7
Seino, Hiroaki, et al. "Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis." Diabetology & metabolic syndrome vol. 8 (2016): 36. doi: https://doi.org/10.1186/s13098-016-0151-7
Seino H, Onishi Y, Naito Y, Komatsu M. Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr. 2016 Jun 01;8:36. doi: 10.1186/s13098-016-0151-7. eCollection 2016. PMID: 27252787; PMCID: PMC4888474.
Copy Download .nbib Format: NLM
Share it on

Diabetol Metab Syndr. 2016 Jun 01;8:36. doi: 10.1186/s13098-016-0151-7. eCollection 2016.

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.

Diabetology & metabolic syndrome

Hiroaki Seino, Yukiko Onishi, Yusuke Naito, Mitsuhisa Komatsu

Affiliations

  1. Seino Internal Medicine Clinic, Fukushima, 9638851 Japan.
  2. Division of Clinical Trials, Division of Diabetes and Metabolism, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan.
  3. Medical Affairs, Sanofi K.K., Tokyo, Japan.
  4. Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Shinshu University School of Medicine, Nagano, Japan.

PMID: 27252787 PMCID: PMC4888474 DOI: 10.1186/s13098-016-0151-7

Abstract

BACKGROUND: The GetGoal-L-Asia and -S trials were multi-center trials conducted in 4 and 16 countries, respectively including Japan that evaluated the efficacy and safety of lixisenatide add-on treatment vs. placebo among patients with type 2 diabetes. The aims of this study were to determine the efficacy and safety of lixisenatide add-on treatment among Japanese patient groups.

METHODS: All Japanese intent-to-treat patients with baseline and endpoint HbA1c measurements were included in the meta-analyses. Subgroup analyses were carried out for patients with low (<8 %) and high (≥8 %) baseline HbA1c levels, low (<25 kg/m(2)) and high (≥25 kg/m(2)) baseline body mass index (BMI), short (<10 years) and long (≥10 years) durations of diabetes, and for those <65 and ≥65 years of age.

RESULTS: The overall study population of Japanese type 2 diabetes patients included 143 patients (mean age: 59.0 years; 35 % female) treated with lixisenatide and 136 patients treated with placebo (mean age: 57.8 years; 32 % female). Among the subgroups, lixisenatide treatment vs. placebo was associated with greater change in HbA1c (Low HbA1c -0.80 %, p < 0.0001; High HbA1c -1.19 %, p < 0.0001; low BMI -0.88 %, p < 0.0001; high BMI -1.28 %, p < 0.0001; short diabetes duration -1.28 %, p < 0.0001; long diabetes duration -0.93 %, p < 0.0001; <65 years: -1.00 %, p < 0.0001; ≥65 years -1.24 %, p < 0.0001). Additionally, among the subgroups, lixisenatide treatment vs. placebo was associated with greater change in post-prandial glucose.

CONCLUSIONS: For Japanese type 2 diabetes patients lixisenatide may be an efficacious and safe add-on therapy leading to improved glycemic outcomes. GetGoal-L-Asia NCT01169779 GetGoal-S NCT00713830.

Keywords: GLP-1 receptor agonists; Lixisenatide; Type 2 diabetes

References

  1. PLoS One. 2013 Sep 06;8(9):e74699 - PubMed
  2. Horm Metab Res. 2015 Nov;47(12 ):895-900 - PubMed
  3. J Diabetes Investig. 2012 Jun 6;3(3):271-5 - PubMed
  4. J Diabetes Investig. 2015 Nov;6(6):623-4 - PubMed
  5. Diabetes Care. 2000 Apr;23 Suppl 2:B21-9 - PubMed
  6. Diabetes Metab Res Rev. 2009 Nov;25(8):705-16 - PubMed
  7. Exp Gerontol. 2013 Sep;48(9):888-97 - PubMed
  8. Diabetes Metab Res Rev. 2011 Jan;27(1):79-84 - PubMed
  9. Expert Rev Clin Pharmacol. 2016;9(3):385-99 - PubMed
  10. Diabetes Metab Syndr Obes. 2013 Nov 22;6:427-33 - PubMed
  11. Diabetes Obes Metab. 2012 Oct;14 (10 ):910-7 - PubMed
  12. Int J Clin Pract Suppl. 2002 Jul;(129):5-11 - PubMed
  13. Diabetes Obes Metab. 2014 Aug;16(8):739-47 - PubMed
  14. Nat Rev Endocrinol. 2012 Dec;8(12):728-42 - PubMed
  15. Int J Mol Sci. 2013 Oct 30;14(11):21525-50 - PubMed
  16. Diabetes Care. 2014;37(3):796-804 - PubMed
  17. Diabetes Care. 2011 May;34 Suppl 2:S120-7 - PubMed
  18. BMJ. 2000 Aug 12;321(7258):405-12 - PubMed
  19. J Diabetes Investig. 2015 Mar;6(2):201-9 - PubMed
  20. Lancet. 2004 Jan 10;363(9403):157-63 - PubMed
  21. BMC Med. 2012 Nov 30;10:152 - PubMed
  22. Cardiovasc Diabetol. 2013 Jan 15;12:15 - PubMed
  23. J Diabetes Complications. 2014 May-Jun;28(3):386-92 - PubMed
  24. Diabetes Res Clin Pract. 2004 Dec;66 Suppl 1:S37-43 - PubMed
  25. Diabetes Obes Metab. 2014 Sep;16(9):769-79 - PubMed
  26. N Engl J Med. 2015 Dec 3;373(23 ):2247-57 - PubMed

Publication Types